Pfizer, Inc.

Equities

PFE

US7170811035

Pharmaceuticals

Real-time Estimate Cboe BZX 10:35:26 2024-06-12 am EDT 5-day change 1st Jan Change
27.74 USD -1.02% Intraday chart for Pfizer, Inc. -6.18% -3.70%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
GSK Starts Appeal Against US State Court Ruling on Zantac Lawsuit MT
GSK Starts Appeal Process Against Delaware Court Decision Allowing Expert Testimonies in Zantac Litigation MT
GSK takes first steps to appeal Zantac ruling in Delaware AN
GSK: decisions in the Zantac (ranitidine) litigation CF
GSK Appeals US Judge's Decision to Allow Plaintiff Expert Testimony in Zantac Litigation MT
GSK Files Application Seeking Right Of Appeal To Delaware Supreme Court On Zantac Litigation RE
Latest trial over Zantac cancer claims called off as plaintiff drops case RE
Pfizer to Pause Sizable Acquisitions as it Integrates Existing Investments, CEO Says MT
Transcript : Pfizer Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 11:20 AM
Pfizer's Paxlovid Failed to Show Clear Benefits Among Long-COVID Patients in Stanford Study MT
US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59 RE
Pfizer's Paxlovid fails as 15-day treatment for long COVID, study finds RE
COVID shots should target JN.1 variants in 2024-25 campaign, US FDA says RE
AbbVie's tight grip on Humira market raises concerns about biosimilars RE
Relay Therapeutics to Collaborate with Pfizer to Evaluate Breast Cancer Treatment DJ
Relay Therapeutics to Collaborate With Pfizer to Evaluate Metastatic Breast Cancer Treatment MT
COVID shots for JN.1 variant neutralize newer strains, vaccine makers say RE
Pfizer: article on Lyme vaccine in The Lancet CF
Pfizer Partners with Abu Dhabi to Advance Research on Sickle Cell Disease MT
Takeda Pharmaceutical, Pfizer Say Phase 3 Trial Assessing Blood Cancer Combination Therapy Met Co-Primary Endpoints MT
COVID shots should target JN.1, KP.2 subvariants in 2024-25 campaign, US FDA staff says RE
Pfizer: positive trial in large B-cell lymphoma CF
Pfizer: promising trial in Hodgkin lymphoma CF
GSK shares tumble 9% after 70,000 Zantac lawsuits allowed to proceed RE
GSK Plans Appeal Against US Judge's Ruling on Jury Trials for Zantac Cases MT
Chart Pfizer, Inc.
More charts
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
28.03 USD
Average target price
31.92 USD
Spread / Average Target
+13.86%
Consensus
  1. Stock Market
  2. Equities
  3. PFE Stock
  4. News Pfizer, Inc.
  5. DA Davidson Raises Price Target on Pfizer to $35 From $30, Maintains Buy/Add Rating